Compare Stocks: HLVX, FHTX, LXEO, and XFOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$7.07	$5.30	$3.27 ▼ $7.61	$419.82M	2.89	298,127 shs	529,538 shs
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
LXEO Lexeo Therapeutics	$4.88	$4.73	$3.99 ▼ $10.99	$400.40M	1.46	919,866 shs	509,587 shs
XFOR X4 Pharmaceuticals	$4.04	$4.08	$2.80 ▼ $4.83	$400.55M	0.37	739,814 shs	1.22 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	+12.94%	+45.77%	+67.54%	+27.16%
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	+1.46%
LXEO Lexeo Therapeutics	0.00%	+0.83%	+4.72%	-4.50%	-0.41%
XFOR X4 Pharmaceuticals	0.00%	-4.27%	+4.94%	0.00%	+3.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$7.07	$5.30	$3.27 ▼ $7.61	$419.82M	2.89	298,127 shs	529,538 shs
HLVX HilleVax	$2.09	$2.09	$1.77 ▼ $2.17	$104.79M	0.77	532,880 shs	N/A
LXEO Lexeo Therapeutics	$4.88	$4.73	$3.99 ▼ $10.99	$400.40M	1.46	919,866 shs	509,587 shs
XFOR X4 Pharmaceuticals	$4.04	$4.08	$2.80 ▼ $4.83	$400.55M	0.37	739,814 shs	1.22 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	+12.94%	+45.77%	+67.54%	+27.16%
HLVX HilleVax	0.00%	0.00%	0.00%	0.00%	+1.46%
LXEO Lexeo Therapeutics	0.00%	+0.83%	+4.72%	-4.50%	-0.41%
XFOR X4 Pharmaceuticals	0.00%	-4.27%	+4.94%	0.00%	+3.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	2.88	Moderate Buy	$11.43	61.65% Upside
HLVX HilleVax	0.00	N/A	N/A	N/A
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	284.22% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	178.47% Upside

Current Analyst Ratings Breakdown

Latest HLVX, FHTX, LXEO, and XFOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	FHTX Foghorn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	XFOR X4 Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/10/2026	XFOR X4 Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/25/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$30.91M	13.58	N/A	N/A	($1.92) per share	-3.68
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
XFOR X4 Pharmaceuticals	$15.85M	25.28	N/A	N/A	$2.13 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	N/A
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest HLVX, FHTX, LXEO, and XFOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/7/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.36	3.36
HLVX HilleVax	N/A	26.39	26.39
LXEO Lexeo Therapeutics	N/A	13.89	13.89
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
HLVX HilleVax	86.42%
LXEO Lexeo Therapeutics	60.67%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	9.02%
HLVX HilleVax	24.90%
LXEO Lexeo Therapeutics	2.00%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	59.38 million	54.03 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable
XFOR X4 Pharmaceuticals	80	99.15 million	98.03 million	No Data

HLVX, FHTX, LXEO, and XFOR Headlines

Recent News About These Companies

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

August 13, 2026 | marketbeat.com

Brookline Capital Markets Predicts XFOR Q3 Earnings

August 13, 2026 | americanbankingnews.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

August 11, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for XFOR FY2029 Earnings

August 10, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Beats Expectations By $0.05 EPS

August 6, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Perceptive Advisors LLC Increases Stake in X4 Pharmaceuticals, Inc. $XFOR

August 2, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

July 2, 2026 | insidertrades.com

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026 | globenewswire.com

Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.01%

June 26, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, FHTX, LXEO, and XFOR Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$7.07 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

HilleVax NASDAQ:HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.88 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

X4 Pharmaceuticals NASDAQ:XFOR

$4.04 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, FHTX, LXEO, and XFOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, FHTX, LXEO, and XFOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, FHTX, LXEO, and XFOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, FHTX, LXEO, and XFOR Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

HilleVax NASDAQ:HLVX

Lexeo Therapeutics NASDAQ:LXEO

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HLVX, FHTX, LXEO, and XFOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HLVX, FHTX, LXEO, and XFOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HLVX, FHTX, LXEO, and XFOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, FHTX, LXEO, and XFOR Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

HilleVax NASDAQ:HLVX

Lexeo Therapeutics NASDAQ:LXEO

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools